Actively Recruiting
Phase 2 Study of Weekly Tirzepatide for Adults with Alcohol Use Disorder and Overweight or Obesity
Led by University of Southern California · Updated on 2025-10-14
42
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of weekly tirzepatide injections compared to placebo on alcohol use and heart-related metabolic health in adults with alcohol use disorder who also have overweight or obesity. This is a Phase 2 randomized controlled trial aiming to understand how tirzepatide might influence drinking behavior and cardiometabolic outcomes in this specific group. Participants will receive either tirzepatide injections at doses of 2.5mg or 5.0mg, or placebo injections, on a weekly basis. The study is randomized and triple-blinded to compare these two groups fairly. The treatment period lasts 8 weeks, with particular focus on the last 4 weeks to assess outcomes. During the trial, participants will attend weekly medication visits where their alcohol consumption, including number of heavy drinking days, drinks per drinking day, and alcohol cravings, will be closely monitored. Researchers will also evaluate changes in drinking risk levels and abstinent days. Safety and adherence will be tracked through regular assessments and questionnaires. The total participant involvement spans the treatment period with systematic monitoring of drinking behavior and cardiometabolic health markers.
CONDITIONS
Brief Title
Tirzepatide for Alcohol Use Disorder
Research Team
C
Christian Hendershot, Ph.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
